Last reviewed · How we verify
Placebo for Saxagliptin
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in clinical trials for type 2 diabetes mellitus.
At a glance
| Generic name | Placebo for Saxagliptin |
|---|---|
| Also known as | Insulin: intermediate-acting or basal or premixed ( include short- or rapid-acting insulin as one component). ≥20 unit/day, ≤150 units/day, Metformin: Glucophage, 500-2500mg/day |
| Sponsor | Prof. Dr. Thomas Forst |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. It relies on the placebo effect—psychological and physiological responses to the expectation of treatment—rather than any direct molecular mechanism. In the context of a Saxagliptin trial, placebo serves as the comparator arm to demonstrate that observed benefits are due to Saxagliptin's DPP-4 inhibition, not expectation alone.
Approved indications
- Control arm in clinical trials for type 2 diabetes mellitus
Common side effects
Key clinical trials
- Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old (PHASE3)
- Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin (PHASE3)
- Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes (PHASE2)
- Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment (PHASE4)
- Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation (PHASE4)
- A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD (PHASE2, PHASE3)
- ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study (NA)
- Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |